Sunshine Biopharma sets up $4 million at-the-market stock sale facility with Aegis Capital

Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. on July 20, 2026, according to an 8-K filing. Under the deal, the Company may, from time to time, sell shares of its common stock, for an aggregate offering price of up to $4,000,000, in at-the-market offerings through Aegis Capital as its exclusive sales agent.¹

Sales can occur through a range of methods, and may be made by any method that qualifies as an at-the-market offering under Rule 415(a)(4), including through Nasdaq or other existing trading markets for the stock.¹ Aegis Capital's compensation is tied to how much stock actually sells: the agent will receive a commission of 3.0% of gross proceeds from any shares sold, plus reimbursement of certain expenses.¹

The filing makes clear there is no guarantee this facility will be used. Neither the company nor the sales agent is obligated to sell or buy any shares, and there is no assurance any shares will be sold, or at what price, amount, or timing.¹

As part of the arrangement, Sunshine Biopharma agreed to indemnify Aegis Capital against certain liabilities arising under securities laws, and to contribute to related payments the agent might owe.¹ Either party can end the deal under its terms, per the filing.

The shares to be sold under this facility draw on the company's existing shelf registration. They will be issued under Sunshine Biopharma's Form S-3 shelf registration statement (File No. 333-284142), filed with the SEC on January 6, 2025 and declared effective on January 15, 2025, along with a prospectus supplement to be filed on July 20, 2026.¹